Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 4/2017

01-08-2017 | Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor)

Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical Implications

Authors: Philip Emmerich, Linda Clipson, Dustin A. Deming

Published in: Current Colorectal Cancer Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

Colorectal cancer (CRC) is a leading cause of cancer-related death and additional treatment options are urgently needed. Cytotoxic chemotherapy has been the mainstay of treatment options for patients for many years, including FOLFOX (leucovorin, 5-fluorouracil (5-FU), and oxaliplatin) or FOLFIRI (5-FU, leucovorin, and irinotecan) Here we review the current clinical use of systemic therapies for metastatic CRC and mechanisms of resistance to these agents.

Recent Findings

Biologic therapies, including anti-angiogenic and anti-epidermal growth factor monoclonal antibodies, have shown increased efficacy for patients with metastatic CRC. Most recently, immunotherapies have also been an option for some patients.

Summary

Identification of molecular markers predictive of response or resistance has led to enhanced ability to treat patients with metastatic CRC in a more personalized fashion.
Literature
1.
2.
Laufman L, Bukowski RM, Collier MA, et al. A randomized double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 1993;11(10):1888.CrossRefPubMed
3.
Venook A, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2017;32:5s (suppl; abstr LBA3).
4.
Heidelberger C, Chaudhuri NK, Danenberg PV, et al. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature. 1957;179:663.CrossRefPubMed
5.
de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15(2):808.CrossRefPubMed
6.
Van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939–50.CrossRefPubMed
7.
Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381–95.CrossRefPubMed
8.
Salonga D, Danenberg KD, Johnson MR, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322–7.PubMed
9.
Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15:3223–9.CrossRefPubMed
10.
Lacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer. 2001;85:827–30.CrossRef
11.
Wei X, Wang W, Wang L, Zhang Y, Zhang X, Chen M, et al. MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDC. Cancer Med. 2016;5(4):693–702.CrossRefPubMedPubMedCentral
12.
Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 2010;103(10):1617–26.CrossRefPubMedPubMedCentral
13.
Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA. 2010;107(49):21098–103.CrossRefPubMedPubMedCentral
14.
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229.CrossRefPubMed
15.
Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharm. 2000;58(5):920–7.
16.
Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, et al. A supset of platinum-containing chemotherapeutic agents kill cells by inducing ribosome biogenesis stress. Nat Med. doi:10.​1038/​nm.​4291.
17.
Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer. 2003;39(1):112–9.CrossRefPubMed
18.
Lenz HJ, Lee FC, Yau L, et al. MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2016;34:(suppl 4S; abstr 493).
19.
Martinez-Balibrea E, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 2015;14(8):1767–76.CrossRefPubMed
20.
Samimi G, Katano K, Holzer AK, Safaei R, Howell SB. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol. 2004;66:25–32.CrossRefPubMed
21.
Plasencia C, Martinez-Balibrea E, Martinez-Cardus A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006;29:225–35.PubMed
22.
Martinez-Balibrea E, Martinez-Cardus A, Musulen E, Gines A, Manzano JL, Aranda E, et al. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int J Cancer. 2009;124:2905–10.CrossRefPubMed
23.
Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421–33.CrossRefPubMed
24.
25.
Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer. 1999;35:1343.CrossRefPubMed
26.
Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692–700.CrossRefPubMed
27.
Fujita K, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol. 2015;21(43):12234–48.CrossRefPubMedPubMedCentral
28.
Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187–91.PubMed
29.
Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841–51.CrossRefPubMed
30.
van Ark-Otte J, Kedde MA, van der Vijgh WJ, et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer. 1998;77:2171–6.CrossRefPubMedPubMedCentral
31.
Chu XY, Suzuki H, Ueda K, et al. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther. 1999;288:735–41.PubMed
32.
Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 2007;98:779–89.CrossRefPubMed
33.
Dexter DL, Wolberg WH, Ansfield FJ, Helson L, Heidelberger C. The clinical pharmacology of 5-trifluoromethyl-2′-deoxyuridine. Cancer Res. 1972;32:247–53.PubMed
34.
Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Parmacol. 2000;59:1227–36.CrossRef
35.
Murakami Y, Kazano H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000;17:277–83.PubMed
36.
Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–19.CrossRefPubMed
37.
Olaf H, et al. Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2. Mol Cancer Ther. 2010;9(4):1047–57.CrossRef
38.
Fakih M. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther. 2013;4:427–38.CrossRef
39.
Gambardella V, Tarazona N, Cejalvo JM, Roselló S, Certantes A. Clinical pharmacokinetics and pharmacodynamics of ramicirumab in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol. 2016;12(4):449–56.CrossRefPubMed
40.
Qu CY, Zheng Y, Zhang Y, Shen F, Cao J, Xu LM. Value of bevacizumab in treatment of colorectal cancer: a meta-analysis. World J Gastroenterol. 2015;21(16):50-72–5080.CrossRef
41.
42.
Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299–309.CrossRefPubMed
43.
Blouw B, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 2003;4:133–46.CrossRefPubMed
44.
Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007;13(5):1552–61.CrossRefPubMed
45.
• Deming D, Holen K. KRAS mutation analysis prior to EGFR-directed therapy for metastatic colorectal cancer: a review and cost analysis. Curr Cancer Ther Rev. 2010;6(4):256–61. This manuscript reviews the ability of KRAS testing to predict resistance to anti-EGFR directed therapies and the immense cost savings as the result of this becoming a standard practice. CrossRef
46.
Tran NH, Cavalcante LL, Lubner SJ, et al. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015;7(5):252–62.CrossRefPubMedPubMedCentral
47.
Al-Shamsi HO, Alhazzani W, Wolff RA. Extended RAS testing in metastatic colorectal cancer-refining the predictive molecular biomarkers. J Gastrointest Oncol. 2015;6(3):314–21.PubMedPubMedCentral
48.
Turk A, Deming DA. BRAF mutation in colorectal cancer. Personalized Medicine in Oncology. 2016;5(1).
49.
• Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34:(suppl; abstr 3504). This study demonstrates the importance of sidedness in the use of anti-EGFR directed therapies for the treatment of metastatic CRC.
50.
Benson AB 3rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(3):370–98.CrossRef
51.
Lee MS, Advani SM, Morris J, et al. Association of primary site and molecular featurs with progression-free survival and overall survival of metastatic colorectal cancer after anti-epidermal growth factor therapy. J Clin Oncol. 34:(suppl;abstr 3506).
52.
Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Oncol Targets Ther. 2016;9:1899–920.CrossRef
53.
•• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. This was the first description of the use of anti-PD1 therapies for the treatment of patients with mismatch repair deficient cancers. CrossRefPubMedPubMedCentral
54.
Overman MJ, Lonardi S, Leone F, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. J Clin Oncol. 2017;35:(suppl 4S;abstract 519).
55.
Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16:121–6.CrossRefPubMed
56.
Restifo NP, Marnicola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenber SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88(2):100–8.CrossRefPubMedPubMedCentral
57.
Garrido F, Aptsiauri N, Doordujin EM, Lora AMG, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44–51.CrossRefPubMedPubMedCentral
58.
Zhang X, Kelaria S, Kerstetter J, Wang J. The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J Gastrointest Oncol. 2015;6(3):307–13.PubMedPubMedCentral
59.
Hope C, Foulcer S, Jagodinsky J, et al. Immunoregulatory roles of versican in the myeloma microenvironment. Blood. 2016;128(5):680–5.CrossRefPubMed
Metadata
Title
Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical Implications
Authors
Philip Emmerich
Linda Clipson
Dustin A. Deming
Publication date
01-08-2017
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 4/2017
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-017-0374-5

Other articles of this Issue 4/2017

Current Colorectal Cancer Reports 4/2017 Go to the issue

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Clinical Target Volume Definition in Preoperative Radiotherapy of Rectal Carcinoma: a Systematic Review

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Colonoscopy and Flexible Sigmoidoscopy in Colorectal Cancer Screening and Surveillance

Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor)

Inflammation and Colorectal Cancer

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Quality Colorectal Cancer Screening: Endoscopic Performance Measures and Beyond

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

The Role of CT Colonography as a Screening Tool for Colorectal Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits